Effectiveness of Bryophyllum in Nocturia-Therapy
NCT04480658 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2022-01-19
Summary
Night-time micturition, called nocturia, is a very common problem that unfavourably influences sleep- and life-qualities. The International Continence Society (ICS) defines nocturia as micturition once or several times during the night. Nocturia is one of the cardinal symptoms of overactive bladder (OAB). Persons with nocturia have the intention to continue sleep after going to the toilet which does not succeed to the same extent, depending on age.
The natural occurrence of the plant, Bryophyllum pinnatum (BP) which is used in this observational study origins from Madagascar as well as in tropical Africa, South America and Asia. In the folk medicine of these countries BP is widely used. BP has a calming, spasmolytic, anti-inflammatory, pain-relieving, diuretic and cytotoxic effects.
According to previous preclinical and clinical studies the inhibiting effect of BP on overactive bladder was proven. The pharmacological effect of this plant on uterine smooth muscle cells, on spontaneous and oxytocin-stimulated contractions, and on detrusor muscle cells in an in-vitro model of the pig's bladder was shown. Smooth muscle relaxation is not only required for preventing premature labour but also for symptom's relief of overactive bladder (OAB). The flavonoid, aglycons and bufadienolides, are components of the pressed juice of the BP leaves that have comparable effects to the standard drug oxybutynin on vesical smooth muscle cells.
Since many year BP is used in obstetrics not only as tocolytics but also as a sedative and sleeping pill.
There are known only few adverse events, such as skin irritation by intravenous application.
The interest in phytotherapeutical drugs for treatment the chronic diseases is very high and Bryophyllum is also frequently used in Switzerland for hyperactive conditions.
In Switzerland, following the vote on complementary medicine on 17.05.2009, alternative treatments will be covered by basic health insurance. Definitive inclusion in the catalogue of benefits will be granted if effectiveness, safety and cost-effectiveness can be demonstrated.
The potential and side-effect profile of BP, as well as the social interest in research into alternative methods is the background to the implementation of this observational study.
Conditions
- Nocturia
- Sleep Disorder
Interventions
- DRUG
-
Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)
Bryophyllum is administered for 3 weeks. Bryophyllum is given in form of capsules, 350mg per capsule, 0-0-2-2/d: 2 capsules 30min. before supper,2 capsules before going to bed. Other Names: Bryophyllum pinnatum/Kalanchoe
Sponsors & Collaborators
-
University of Zurich
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-01
- Primary Completion
- 2021-02-18
- Completion
- 2022-01-14
Countries
- Switzerland
Study Locations
More Related Trials
-
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
NCT02841709 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep
NCT01196650 ·Status: COMPLETED ·Phase: PHASE2
-
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
NCT00606593 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness
NCT00401284 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Chronic Hypnotic Use 2
NCT02456532 ·Status: COMPLETED ·Phase: PHASE4
-
An Exploratory Study of NBI-34060 Capsules and Next Day Functioning
NCT00525941 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
NCT01995838 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Sleep-relieving Effect of Banana Peel Extract
NCT05130359 ·Status: COMPLETED ·Phase: NA
-
Melatonin for Nocturia in Parkinson's Disease
NCT02359448 ·Status: UNKNOWN ·Phase: PHASE2
-
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
NCT00352144 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia
NCT00253968 ·Status: COMPLETED ·Phase: PHASE3
-
Sleep and Breathing in the General Population - Chemical Stimuli
NCT04720547 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of LY2624803 in Japanese Participants With Transient Insomnia
NCT01784614 ·Status: COMPLETED ·Phase: PHASE1
-
Xyrem for Treatment Refractory Insomnia Due to PTSD
NCT00330291 ·Status: WITHDRAWN ·Phase: PHASE2
-
Improving Patient Safety by Supporting Older Adults in Managing Sleep Problems.
NCT06584513 ·Status: RECRUITING ·Phase: NA
-
Effect of Countermeasures on Nocturnal Driving Performance
NCT01070004 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety Study of Propofol Infusion for Refractory Chronic Primary Insomnia
NCT02043977 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension
NCT02963181 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Non-deceptive Application of Placebos in Insomnia
NCT03616652 ·Status: COMPLETED ·Phase: NA
-
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078 ·Status: RECRUITING ·Phase: PHASE2
-
A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
NCT01463098 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia
NCT00913614 ·Status: COMPLETED ·Phase: PHASE1
-
Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
NCT00608985 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
NCT00368056 ·Status: COMPLETED ·Phase: PHASE3